PFE - Pfizer COVID-19 antiviral priced at under $25 per course by generic drugmakers

A group of generic drug manufacturers agreed to make versions of Pfizer’s (NYSE:PFE) COVID-19 antiviral Paxlovid at under US$25 per treatment course, The Clinton Health Access Initiative (CHAI) announced on Thursday. The health organization did not disclose the names of the drugmakers because they are yet to receive the regulatory nod and are still in the early stages of development.   Following a licensing deal between Pfizer (PFE) and the UN-backed Medicines Patent Pool (MPP), 35 companies signed agreements to manufacture the generic versions of the oral COVID-19 pill. Companies such as Teva Pharmaceutical (TEVA), Shanghai Fosun Pharmaceuticals (OTCPK:SFOSF), and Amneal Pharmaceuticals (AMRX) were among the 35 drugmakers that were part of the sublicence agreements, aimed at serving over 95 low- and middle-income countries. CHAI said that the drugmakers will allocate a production capacity to manufacture 4.5 million treatment courses per month for these countries. However, the US$25 price ceiling applies only

For further details see:

Pfizer COVID-19 antiviral priced at under $25 per course by generic drugmakers